Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Molecular Neurobiology|June 1, 2026
Single-Nucleus Profiling Reveals a BBB Senescence Unit Driving AD Pathology in Human BrainYuanwei Zhang, Zhongman Jin, Ruizhen Rao, et al.Allergologia Et Immunopathologia|July 5, 2022
Correlation analysis of TGF-β1, MMP-9, TIMP-1, IL-1, IL-4, IL-6, IL-17, and TNF-α in refractory chronic rhinosinusitis: A retrospective studyWulin Wen, Simin Zhu, Ruixia Ma, et al.Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery|July 8, 2024
[Research on the classification model of chronic sinusitis based on VGG]Ning Zhang, Ruixia Ma, Hailing Ren, et al.Journal of Agricultural and Food Chemistry|December 6, 2022
Alterperylenol as a Novel Thioredoxin Reductase Inhibitor Induces Liver Cancer Cell Apoptosis and FerroptosisJunmin Xi, Li-Li Tian, Jiahui Xi, et al.Molecular Medicine Reports|September 9, 2020
Ghrelin system is involved in improvements in glucose metabolism mediated by hyperbaric oxygen treatment in a streptozotocin‑induced type 1 diabetes mouse modelLimin Song, Junhua Yuan, Yuan Liu, et al.Frontiers in Pharmacology|February 28, 2025
UPLC-MS/MS method for simultaneous determination of pyrantel, praziquantel, febantel, fenbendazole and oxfendazole in dog plasma and its application to a bioequivalence studyFengyichi Zhang, Fanxi Guo, Xinyu Zhao, et al.The World Allergy Organization Journal|September 23, 2020
Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trialHongfei Lou, Xueyan Wang, Qingyu Wei, et al.The World Allergy Organization Journal|February 24, 2026
Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitisYutong Sima, Xueyan Wang, Tao Zhang, et al.BMJ Open|June 22, 2022
Awareness about laryngopharyngeal reflux disease among Chinese otolaryngologists: a nationwide surveyShuifang Xiao, Jinrang Li, Hongliang Zheng, et al.Nature Medicine|April 4, 2025
Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trialYuan Zhang, Jingyun Li, Menglin Wang, et al.Pageof 9